Status – in Start-up
A site-sponsored Phase Ib open-label trial to investigate the use of intravenous CAVATAK® in combination with pembrolizumab (KEYTRUDA™) for the treatment of patients with advanced Non Small Cell Lung Cancer (NSCLC) is in start-up at the Olivia Newton-John Cancer Research Institute (ONJCRI) in Melbourne, Australia.
The trial is designed to assess the safety and tolerability of the CAVATAK/KEYTRUDA combination therapy and will be conducted in two parts: the first part will assess the safety of three ascending dose levels of intravenously-delivered CAVATAK in combination with a fixed dose of pembrolizumab. Once a safe dose of CAVATAK has been determined, the second part will enroll additional subjects to further evaluate safety and assess efficacy by overall response and changes in the tumor microenvironment. The study may enrol up to 30 patients.
For information about this trial, please visit the Clinical Trial website at clinicaltrials.gov, Identifier NCT02824965.